BioMedNewsBreaks

ThursdayFeb 05, 2026 9:20 am

BioMedNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Submits IND Amendment for Planned Phase 2a Trial of TTX-MC138 in Colorectal Cancer

TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug ("IND") application amendment to the U.S. Food and Drug Administration for a planned Phase 2a clinical trial of its lead candidate, TTX-MC138, to be conducted by Quantum Leap Healthcare Collaborative within the PRE-I-SPY program. The dose-expansion study is expected to enroll up to 45 colorectal cancer patients who have completed standard curative-intent therapy and test positive for circulating tumor DNA ("ctDNA"), a marker associated with minimal residual disease ("MRD") and cancer recurrence, with the trial planned to begin in the first half of 2026 under the leadership of…

Continue Reading

ThursdayFeb 05, 2026 9:10 am

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports New Cellular Data Demonstrating Coordinated Intracellular Zinc Increase and Iron Reduction With Telomir-Zn

Telomir Pharmaceuticals (NASDAQ: TELO) announced new cellular study results showing that Telomir-1, administered as Telomir-Zn, induces a rapid and coordinated redistribution of intracellular metals, simultaneously increasing zinc levels while reducing redox-active ferrous iron in living cells. The company said the findings extend its previously reported iron-reduction data by demonstrating, for the first time, a coupled intracellular metal-modulating mechanism rather than simple extracellular chelation, supporting a potential upstream approach to addressing oxidative stress, mitochondrial dysfunction, epigenetic instability, and genomic damage associated with cancer and aging. To view the full press release, visit https://ibn.fm/MPLBG About Telomir Pharmaceuticals Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is…

Continue Reading

TuesdayFeb 03, 2026 10:00 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution

Oragenics (NYSE American: OGEN) announced that it has engaged DUCK FLATS Pharma as its U.S. Investigational New Drug readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design as the Company advances its intranasal concussion therapy ONP-002 toward U.S.-based development, with the engagement intended to align the Company’s upcoming Phase 2a clinical trial in Australia with its U.S. regulatory strategy and support progression toward a future U.S. Phase 2b trial and later-stage development. To view the full press release, visit https://ibn.fm/1n4Ja About Oragenics, Inc. Oragenics, Inc. is a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal…

Continue Reading

MondayFeb 02, 2026 9:40 am

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing intranasal therapeutics for neurological disorders, announced its participation at the SCOPE Summit 2026, the 17th annual Summit for Clinical Ops Executives organized by the Cambridge Healthtech Institute, being held Feb. 2–5, 2026, in Orlando, Fla. The company plans to engage with leaders across biopharma, clinical research, regulatory affairs, and clinical technology as it advances its proprietary intranasal delivery platform and prepares for a Phase 2a clinical trial in Australia of ONP-002, its first-of-its-kind therapeutic candidate for concussion and mild traumatic brain injury, areas with significant unmet medical need and no FDA-approved…

Continue Reading

MondayFeb 02, 2026 9:30 am

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Mission Matters Podcast Interview With President Anil Diwan

NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast, where he discussed the company’s mission to revolutionize antiviral treatment through its nanoviricide platform and highlighted progress of lead drug candidate NV-387. During the interview, Dr. Diwan explained how nanoviricides are designed to prevent viral escape, function independently of patient immune status, and offer broad-spectrum potential across patient populations, from infants to geriatrics. He noted that NV-387 has demonstrated efficacy against multiple unrelated viruses in lethal animal models, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles, and has completed a Phase…

Continue Reading

FridayJan 30, 2026 1:41 pm

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q® Cancer assays to government agencies in France. The submission will be actively supported by Hospices Civils de Lyon, France’s second-largest university hospital system, and will run in parallel with the previously announced clinical certification process at HCL. HCL researchers said the Nu.Q® Cancer test is intended to be introduced into routine, reimbursed clinical practice for lung cancer management in France following completion of the reimbursement and certification processes. Data generated through collaboration with Volition indicate that measuring methylated nucleosome biomarkers at the time of non-small cell lung cancer diagnosis…

Continue Reading

FridayJan 30, 2026 10:45 am

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting 

Nutriband (NASDAQ: NTRB) (NASDAQ: NTRBW) provided shareholders with an update following its 2026 Annual Shareholders Meeting held Jan. 24, 2026, in Orlando, Florida, highlighting the appointment of two new directors, Alessandro Puddu and Viorica Carlig, and outlining key progress in the development of AVERSA(TM) FENTANYL. During 2025, the company strengthened its exclusive partnership with Kindeva, completed commercial manufacturing scale-up, expanded global patent protection including new U.S. and Macao patents, engaged with the U.S. Food and Drug Administration through a Type C meeting, and advanced branding initiatives for AVERSA(TM) FENTANYL. Looking ahead to 2026, Nutriband plans to advance toward an NDA filing by extending patent protection potentially to 2046, manufacturing…

Continue Reading

ThursdayJan 29, 2026 12:38 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM) 

Cutaneous T-cell lymphoma, or CTCL, is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages. A recent article discussed Soligenix’s (NASDAQ: SNGX) efforts to develop therapies aimed at addressing critical gaps in rare disease treatment, including CTCL.  The publication reads, “Within a challenging diagnostic and treatment landscape, Soligenix is advancing a novel therapeutic approach for CTCL through its development of HyBryte(TM), also known as synthetic hypericin. HyBryte is a visible light-activated photodynamic therapy designed for the treatment of early-stage CTCL. Unlike traditional ultraviolet-based phototherapies, which can carry long-term safety risks with cumulative exposure, HyBryte is activated by visible light in the red-yellow spectrum,…

Continue Reading

TuesdayJan 27, 2026 10:10 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287

CNS Pharmaceuticals (NASDAQ: CNSP) released a Letter to Shareholders from newly appointed President and Chief Executive Officer Rami Levin outlining a comprehensive strategic evaluation of the Company’s pipeline, operations and capital allocation priorities. The letter emphasizes a disciplined, patient-first approach centered on optimizing TPI 287 as the Company’s lead asset, refining its development and regulatory pathway, prioritizing high-value indications, and aligning resources toward milestone-driven execution, while also selectively evaluating pipeline expansion opportunities to support long-term shareholder value creation. To view the full press release, visit https://ibn.fm/mEy9f About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline…

Continue Reading

FridayJan 23, 2026 9:10 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Engages IBN for Corporate Communications Support

Earth Science Tech (OTC: ETST), a strategic holding company advancing a portfolio of operating businesses within regulated healthcare markets, announced that it has engaged InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, to assist with its corporate communications strategy, reflecting the company’s focus on execution, compliance and disciplined scaling across licensed pharmaceutical compounding, digital health and telemedicine platforms, specialty healthcare services and complementary assets, with hands-on operational oversight through wholly owned and majority-owned subsidiaries aimed at building sustainable revenue streams and long-term shareholder value. To view the full press release, visit https://ibn.fm/5qFTn About Earth Science Tech, Inc. Earth Science…

Continue Reading